Sanofi launches diabetes drug Soliqua in India, aiming to improve glycemic control

Sanofi India launches Soliqua, a once-daily injectable diabetes drug, in the country. The medication costs Rs 1,850 per pen and is indicated for adults with type 2 diabetes who are poorly controlled with oral or injectable therapies.

Sanofi India on Tuesday said it has launched its diabetes drug Soliqua in the country.

The company introduced the medication after receiving the marketing authorisation from the Central Drugs Standard Control Organization (CDSCO) earlier last year.

Soliqua is a once-daily injectable combination drug containing insulin, glargine 100 units/ml, which is a long-acting basal insulin and lixisenatide, a GLP-1 receptor agonist.

It is available at a therapy cost of Rs 1,850 per pen.

''The inclusion of Soliqua to our comprehensive diabetes portfolio (orals and injectables) eases therapy initiation, which helps those prescribed, keep their blood sugar in control more effectively,'' Sanofi India Head Diabetes Business Unit Cyrus Aibara said in a statement.

Soliqua is indicated as a treatment in adults with obesity and type 2 diabetes mellitus, to improve glycemic control as an adjunct to diet and exercise, in those who are insufficiently controlled on oral or injectable therapies.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)